Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics
The DOI matches its Crossref record, with a small difference in title or year; 199 of the 199 references it cites were found in a registry or an index.
Abstract
Drug-induced vascular injury (DIVI) is a recurrent challenge in the development of novel pharmaceutical agents. Although DIVI in laboratory animal species has been well characterized for vasoactive small molecules, there is little available information regarding DIVI associated with biotherapeutics such as peptides/proteins or antibodies. Because of the uncertainty about whether DIVI in preclinical studies is predictive of effects in humans and the lack of robust biomarkers of DIVI, preclinical DIVI findings can cause considerable delays in or even halt development of promising new drugs. This review discusses standard terminology, characteristics, and mechanisms of DIVI associated with biotherapeutics. Guidance and points to consider for the toxicologist and pathologist facing preclinical cases of biotherapeutic-related DIVI are outlined, and examples of regulatory feedback for each of the mechanistic types of DIVI are included to provide insight into risk assessment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of vesicant intravenous infusions during hospital attention is another common factor potentially affecting this group of population, which could specially be present in patients receiving IV chemotherapy.52”
From Defining risk factors associated with difficult peripheral venous Cannulation: A systematic review and meta-analysis (2020) · cites this paper as [52]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Blockade of PD-1, a receptor expressed by T cells, modulates immune responses, and organ inflammation has been noted preclinically with this class of agents due to pharmacologic activity (Topalian et al. 2012).”
Background2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
Jennette, J. C., Falk, R. J., Bacon, P. A., Basu, N., Cid, M. C., Ferrario, F., Flores‐Suarez, L. F., Gross, W. L., Guillevin, L., Hagen, E. C., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37715 · Cited by 6,631
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654 · cited 2×
“General details on specific complement biology will not be reviewed in this article but can be found in relevant review articles (Harboe et al. 2004, 2009; Noris and Remuzzi 2013; Ricklin et al. 2010; Ricklin and Lambris 2013; Volanakis 2014).”
BackgroundEndothelial cells in physiology and in the pathophysiology of vascular disorders.
Cines, D. B., Pollak, E. S., Buck, C. A., Loscalzo, J., Zimmerman, G. A., McEver, R. P., Pober, J. S., Wick, T. M., Konkle, B. A., Schwartz, B. S., et al. (1998) · PubMed · doi:10.1182/blood.v91.10.3527 · Cited by 2,256
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“Probably, the most publicized case of clinical vascular damage due to proinflammatory peptide therapies involved a clinical trial in patients administered the anti-CD28 product TGN1412, and which resulted in effects that were not predicted preclinically (Suntharalingam et al. 2006).”
BackgroundAngiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924 · cited 1×
“Smooth muscle cells (SMCs) regulate vascular tone and have receptors for endogenous vasoconstrictors such as angiotensin, endothelin, and epinephrine, and are also a target for NO and ion channel openers (Nguyen Dinh Cat and Touyz 2011; Galley and Webster 2004; Mehta and Griendling 2007).”
BackgroundRobbins and Cotran Pathologic Basis of Disease
Hoda, S. A., & Hoda, R. S. (2005) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000155072.86944.7d · Cited by 1,571
Swine as Models in Biomedical Research and Toxicology Testing
Swindle, M. M., Makin, A., Herron, A. J., Clubb, F. J., & Frazier, K. S. (2012) · Veterinary Pathology · doi:10.1177/0300985811402846 · Cited by 1,357 · cited 2×
“Necrosis or thrombosis may occur and laminar thickening of the adventitia has been described (Swindle et al. 2012).”
BackgroundSelf-citationEffects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355 · cited 1×
“Drug or protein aggregates within the dosing solution can further enhance the immune recognition of a substance as ‘‘foreign’’ even without the participation of ADA (Rosenberg 2006; Leach 2013).”
BackgroundJennette, J. C., & Falk, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711203372106 · Cited by 1,323
Research works printed but not linked: 34
- Albassam M. A., 1993, Lab Anim Sci, 43, 628
- Alexander N. J., 1985, Lab Anim Sci, 35, 465
- Alpers C. E., 2009, Pathologic Basis of Disease, Professional Edition, 930
- Anderson T. D., 1989, Lab Invest, 60, 331
- Barron K., 1988, J Rheumatol, 15, 1243
- Blann A. D., 2005, Thromb Haemost, 3, 228
- Bugelski P. J., 2004, Curr Opin Mol Ther, 6, 10
- Casselman B. L., 1995, J Lab Clin Med, 126, 495
- Cines D. B., 1998, Blood, 91, 3527
- Conn D. L., 1976, Mayo Clin Proc, 56, 511
- Daguès N., 2007, Toxicol Sci, 107, 298
- Day C. J., 2003, Clin Exp Rheumatol, 21, S35
- Dhir V., 2012, J Immunol, 9, 34
- Enerson B., 2010, Toxicologist, 114, 7
- Erdbruegger U., Dhaygude A., Woywodt A. (2011). Markers of Vascular Damage and Repair, Advances in the Etiology, Pathogenesis and Pathology of Vasculitis (Amezcua-Guerra Luis M.Dr, ed.), pp. 179–94. Elsevier, ISBN: 978-953-307-651-5.
- Frazier K. S., 2014, Toxicol Pathol
- Frazier K. S., 2013, Toxicologic Pathology: Preclinical Safety Assessment, 426
- Galaria N. A., 2000, J Rheumatol, 27, 2041
- Gimbrone M. A., 1997, J Clin Invest, 100, S61
- Jeppesen G., 2014, Toxicol Pathol, 42
- Jennette J. C., 1995, Ann Acad Med Singapore, 24, 248
- Johansson S., 1981, Acta Path Microbial Scand Sect A, 89, 185
- Kerns W. D., 1989, Am J Pathol, 135, 339
- Kumar V., 2010, Robbins and Cotran Pathologic Basis of Diseaes, 183
- 10.1002/1529-0131(199904)42:3<561::aid-anr22>3.0.co;2-x · doi:10.1002/1529-0131(199904)42:3<561::aid-anr22>3.0.co;2-x
- Mannik M., 1987, J Rheumatol, 14, 35
- Moyer C. F., 1987, Am J Pathol, 127, 229
- Radic M., 2012, Neth J Med, 70, 12
- Sivakumar P. V., 2013, Comp Med, 63, 13
- Stewart R. J., 1994, Kidney Int Suppl, 45, S37
- Stills H. F., 1983, Am J Pathol, 113, 222
- Wu H., 2007, Clin Lab, 53, 285
- Yuhas E. M., 1985, Am J Pathol, 119, 83
- Zhang J., 2002, Toxicologist, 66, 15
Cited by
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
Poller, W., Dimmeler, S., Heymans, S., Zeller, T., Haas, J., Karakas, M., Leistner, D.-M., Jakob, P., Nakagawa, S., Blankenberg, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx165 · Cited by 408
Rodríguez-Calero, M. A., Blanco-Mavillard, I., Morales-Asencio, J. M., Fernández-Fernández, I., Castro-Sánchez, E., & de Pedro-Gómez, J. E. (2020) · Heart & Lung · doi:10.1016/j.hrtlng.2020.01.009 · Cited by 78
Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C. S., Scicchitano, M. S., Weaver, J. L., Zabka, T. S., & Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570341 · Cited by 53
“The interpretation of drug-induced vascular lesions in NHPs is made challenging by the occasional observation of spontaneous vascular lesions in cynomolgus macaques (Frazier et al. 2015).”
BackgroundSelf-citationWoicke, J., Al-Haddawi, M., Bienvenu, J.-G., Rae, J. M. C., Chanut, F. J.-A., Colman, K., Cullen, J. M., Davis, W. P., Fukuda, R., Huisinga, M., et al. (2021) · Toxicologic Pathology · doi:10.1177/0192623320968181 · Cited by 49
Colman, K., Andrews, R. N., Atkins, H., Boulineau, T., Bradley, A., Braendli-Baiocco, A., Capobianco, R., Caudell, D. L., Cline, M., Doi, T., et al. (2021) · Journal of Toxicologic Pathology · doi:10.1293/tox.34.1s · Cited by 50
Self-citation
Metadata
- Authors
- Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Ionis Pharmaceuticals (United States) (US)
- WIL Research Europe, Saint-Germain-Nuelles, France
- MedImmune, Cambridge, UK
- Pfizer (United States) (US)
- Raritan, Somerset, New Jersey, USA
- United States Food and Drug Administration (US)
- Genentech (US)
- Corresponding author
- Frazier, Kendall S.
- ORCID
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2015-02-26
- Volume
- 43
- Issue
- 7
- Pages
- 915-934
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2097919342
- Cited by
- 35
- References
- 199
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2022: 1 · 2021: 5 · 2020: 5 · 2019: 7 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 1
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Toxicologic Pathology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- drug-induced vascular injury, biologic therapy, immunoglobulins, peptides, preclinical toxicology, regulatory toxicology, biomarkers, risk assessment, drug development, feedback regulation
- MeSH terms
- Animals, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Vascular System Injuries, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics. https://app.cochat.ai/papers/10.1177/0192623315570340
- The paper
- Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S. (2015). Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics. Toxicologic Pathology. https://doi.org/10.1177/0192623315570340
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.